Company

Cognito Therapeutics

MIT spinout developing a noninvasive sensory stimulation device using light and sound at 40Hz to treat Alzheimer's disease and other neurological conditions

Healthcare & Biotech

People

Christian Howellceo

Funding History

Mar 5, 2026

Cognito Therapeutics oversubscribed a $100M+ fundraising round. The company is developing a noninvasive light-and-sound therapy device for Alzheimer's disease. The company plans to read out its Phase 3 trial results in August 2026, file with the FDA in November 2026, and target approval by mid-2027.

100M

News

Interviews (1)

Cognito Therapeutics raises $100M for FDA-bound light-and-sound Alzheimer's device

5 Mar 2026